Another similar substance under development is TDT-067 by Celtic Pharma. A press release from 2009 can be viewed at http://www.drugs.com/clinical_trials/celtic-pharma-successful-outcome-phase-ii-trial-topical-onychomycosis-6910.html . The substance as described by the company itself:
"Innovative drug carriers called Transfersomes® have been developed for the non?invasive delivery of agents into or through the skin. Transfersome® preparations consist of complex lipid vesicles, which are able to cross the skin permeability barrier, the stratum corneum, driven by the transcutaneous water gradient. TDT-067 (terbinafine in Transfersomes®) is a novel, epicutaneously applied carrier-based dosage form of terbinafine in development for the treatment of onychomycosis of the toenail and fingernail."
This does not seem to work with nanoparticles but instead with various substances that should work as carriers, penetrating the skin and transporting terbinafine with it to the seat of the fungal infection. Sounds interesting, and is now in phase 3 trials.
IDP-108 is being developed by Dow Pharmaceutical Sciences and is in phase 3 trials. Little can be found about this one, but initial reports from the manufacturer looks good, for what that's worth. Remember that things may look extra good in the beginning. But then again, if it did not work at all, they would not keep investing in it.
Studies have been done on the tolerability of stronger terbinafine solutions, 10 % as opposed to lamisil cream that carries 1 % terbinafine, the study can be seen at http://www.clinicaltrials.gov/show/NCT00443898, although the results cannot be viewed there.
I will keep posting useful links and also provide more extensive info on the mentioned treatments and substances.